Safety, Tolerability, Kinetics and Efficacy Study of Hoodia Gordonii Purified Extract (PYM50717)

This study has been completed.
Sponsor:
Collaborators:
Phytopharm
Covance
Information provided by:
Unilever R&D
ClinicalTrials.gov Identifier:
NCT01306422
First received: February 25, 2011
Last updated: February 28, 2011
Last verified: February 2011
  Purpose

The objective of this clinical study was to assess the safety, tolerability, efficacy (effects on appetite scores, food intake) and plasma kinetics of Hoodia gordonii purified extract (H.g.PE), when consumed twice-daily for 2 or 15-days.


Condition Intervention
Appetite Depressant
Overweight
Body Weight
Other: Hoodia gordonii purified extract (H.g.PE)
Other: Placebo yogurt drink

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Two Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Kinetics and Efficacy of Twice-Daily Repeat Intake of 1110 mg of Hoodia Gordonii Purified Extract (PYM50717)

Further study details as provided by Unilever R&D:

Primary Outcome Measures:
  • Safety and tolerability of 2 and 15 day repeat consumption of Hoodia gordonii Purified Extract (H.g.PE) [ Time Frame: 41 days ] [ Designated as safety issue: Yes ]
    Safety and tolerability (Adverse Events (AEs), vitals signs, Electrocardiogram (ECG), laboratory assessments) of twice daily consumption of 1110 mg of formulated Hoodia gordonii purified extract (H.g.PE) consumed over a period of 2 or 15 days were assessed up to 41 days after start of the intervention

  • Efficacy of 15-day repeat consumption of H.g.PE [ Time Frame: 15 days ] [ Designated as safety issue: No ]
    Efficacy of twice daily consumption of 1110 mg of formulated H.g.PE during 15-day repeat intake was assessed. Appetite scores, ad libitum energy intake, body weight and body composition were assessed during the 15-day intervention.


Secondary Outcome Measures:
  • Assessment of the pharmacokinetics of PYM50057 a marker of the steroid glycosides in H.g.PE [ Time Frame: 41 days ] [ Designated as safety issue: No ]
    Kinetic parameters were calculated on Days 5 and 19 based on the individual plasma concentration-time profiles of the steroid glycoside, PYM50057. Maximum measured plasma concentration (Cmax), time of Cmax (tmax), area under the concentration-time curve (AUC), apparent terminal phase rate constant (Kel), absorption rate constant (Ka),the apparent first order elimination rate constant (λz) and the overall apparent elimination half-life (t1/2) were assessed. Samples were taken up to 41 days after start of the intervention.


Enrollment: 64
Study Start Date: March 2008
Study Completion Date: October 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Stage 2: Placebo
Placebo product, twice-daily, 65 minutes before breakfast and dinner
Other: Placebo yogurt drink
Placebo product (yogurt drink matching the H.g.PE extract formulated yogurt drink in nutritional composition and taste. Placebo is consumed twice-daily, 65 minutes before breakfast and dinner for 15 days.
Active Comparator: Stage 2: H.g.PE 1110 mg b.d.
Hoodia gordonii Purified Extract (H.g.PE) formulated product (1110 mg), twice-daily, 65 minutes before breakfast and dinner
Other: Hoodia gordonii purified extract (H.g.PE)
H.g.PE(1110 mg) formulated yogurt drink, twice-daily, 65 minutes before breakfast and dinner, for 15 days
Other Names:
  • PYM50717
  • H.g.PE
  • Hoodia gordonii Purified Extract
Placebo Comparator: Stage 1: placebo, breakfast & dinner
Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
Other: Placebo yogurt drink
Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
Active Comparator: Stage 1: H.g.PE 1110 mg breakfast/dinner
Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
Other: Hoodia gordonii purified extract (H.g.PE)
H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
Other Names:
  • PYM50717
  • H.g.PE
  • Hoodia gordonii Purified Extract
Placebo Comparator: stage 1: Placebo breakfast/lunch
Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
Other: Placebo yogurt drink
Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
Active Comparator: Stage 1: H.g.PE 1110 mg breakfast/lunch
Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
Other: Hoodia gordonii purified extract (H.g.PE)
H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
Other Names:
  • PYM50717
  • H.g.PE
  • Hoodia gordonii Purified Extract

Detailed Description:

A two stage randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, kinetics and efficacy of twice-daily repeat intake of formulated Hoodia gordonii purified extract (H.g.PE) (PYM50717) administered twice daily for 2 or 15 days to healthy, overweight females aged 18 to 50 years with a body fat of 25-45%.

Stage 1 (pilot): Placebo controlled, double blind comparison to assess the effect of timing of product administration (i.e. breakfast and lunch vs breakfast and dinner).

Stage 2 (main study): Placebo controlled double blind comparison with product administered with breakfast and dinner.

A total of 64 subjects were included in this study; stage 1: n=15, stage 2: n=49. Treatment groups in stage 2 were matched for percentage body fat.

Stage 1:

  • H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch (n = 4).
  • Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch (n = 3).
  • H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner (n = 5).
  • Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner (n = 3).

Stage 2:

  • H.g.PE formulated product (1110 mg), twice daily (n=25)for 15 days
  • Placebo product , twice daily (n=24),for 15 days
  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy females between the ages of 18 and 50 years.
  • Body fat between 25% and 45% as assessed by Dual Energy X-ray absorptiometry (DEXA) scan at Screening.
  • Stable body weight for at least two months prior to Screening (weight loss or gain >5% was considered unstable).
  • Regularly consumed at least three meals per day, including breakfast.
  • Agreed to abstain from strenuous exercise throughout the entire study.

Exclusion Criteria:

  • Subjects who were pregnant, lactating or were not willing to use two contraceptives (including at least one barrier contraceptive) starting at least 14 days before study product administration (Day 1) and until at least 30 days following study product administration (except subjects who were surgically sterilized or were more than one year post-menopausal).
  • Subjects who were taking any prescription or over the counter medications (with the exception of hormonal contraceptives) (including supplements, especially as related to weight management [eg, ephedrine, caffeine, synephrine]) within one week prior to Visit 2 (Day 1), or antibiotics <3 months prior to Day 1, or planned to do so during the course of the study.
  • Smokers, or ex-smokers who smoked any cigarettes in the past six months prior to study product administration and/or who used another form of nicotine-containing product.
  • Fasting blood glucose > 7 mmol/L (126 mg/dL) at Screening.
  • Psychiatric disorders that could have interfered with the subject's compliance to the requirements of the protocol, at the discretion of the Investigator.
  • Used or planned to use any medically prescribed diet or weight-loss diet or made any attempt to control diet at Screening and during the entire study.
  • Strenuous exercise >5 hours per week (eg, sports).
  • Restrained eating behavior determined by a score of ≥16 on the Revised Restraint Scale
  • a low score on the Food Action Rating Scale
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01306422

Locations
United States, Wisconsin
Covance CRU
Madison, Wisconsin, United States, 53704
Sponsors and Collaborators
Unilever R&D
Phytopharm
Covance
Investigators
Principal Investigator: Debra Mandarino, MD Covance CRU, Madison WI
Study Chair: Leo Abrahamse, PhD Unilever R&D Vlaardingen
  More Information

No publications provided by Unilever R&D

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Leo Abrahamse, PhD, Unilever R&D Vlaardingen
ClinicalTrials.gov Identifier: NCT01306422     History of Changes
Other Study ID Numbers: 07044V
Study First Received: February 25, 2011
Last Updated: February 28, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Unilever R&D:
hoodia gordonii
energy intake
food intake
efficacy
body weight
functional food
plant extract
safety
steroid glycosides
tolerability

Additional relevant MeSH terms:
Overweight
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on September 18, 2014